Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Race to slow the heart: Beta-Blockers vs ivabradine before CT scans

NCT ID NCT07268170

Symptom relief Sponsor: Gødstrup Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial compares three common heart-rate-lowering drugs—metoprolol, atenolol, and ivabradine—to see which one reduces heart rate fastest before a cardiac CT scan. About 350 adults aged 30–80 with a heart rate over 65 beats per minute will receive one of the drugs or a placebo. The goal is to improve scan quality by quickly achieving a lower heart rate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metoprolol, atenolol, or ivabradine
What this could lead to
If successful, this could help doctors choose the best drug to quickly lower heart rate before a cardiac CT, improving scan quality and patient comfort.
What could go wrong
This is a small, early-phase study focused on a short-term procedure, not a long-term treatment. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who are to undergo Cardiac CT * Sinus rhythm with heart rate \> 65 bpm on ECG * Competent patients who have given written informed consent Exclusion Criteria: * Age \> 80 years * Age \< 30 years * Heart rate \> 100 bpm * BMI \> 35 * Previous percutaneous coronary intervention (with or without stent) * Previous CABG * Known ischemic heart disease * Pacemaker * Acute coronary syndrome * Known allergy to beta-blockers * Known allergy to ivabradine * Known allergy to used radiographic contrast agents * Pregnant, including potentially pregnant, or breastfeeding (potentially pregnant patients will undergo pregnancy testing) * Heart failure with systolic left ventricular ejection fraction \< 45% * Reduced kidney function with estimated glomerular filtration rate (eGFR) \< 40 ml/min * Regular treatment with beta-blockers * Regular treatment with ivabradine * Regular treatment with non-dihydropyridine calcium antagonists (Verapamil and Diltiazem) * Regular treatment with Cordarone * Contraindications for beta-blockers or ivabradine: * Severe asthma * Severe COPD * Sick sinus syndrome * Sinoatrial block (1st degree AV block) * Advanced AV block (2nd or 3rd degree) * Hypotension (systolic blood pressure \< 110 mmHg) * Severe heart failure * Severe restrictive cardiomyopathy * Severe aortic stenosis * Severe circulatory disturbances * Severe metabolic conditions * Untreated pheochromocytoma * Concurrent treatment with potent inhibitors of CYP3A4 * Concurrent treatment with potent inhibitors of MAO inhibitors, * Concurrent treatment with potent inhibitors of CYP2D6 inhibitors * Concurrent treatment with potent inhibitors of intravenous calcium antagonists type I or III

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD) Ischemic heart disease (IHD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Clinic of Ischemic Heart Disease

    Herning, 7400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.